{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:22:23Z","timestamp":1775244143105,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.diagmicrobio.2018.11.021","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T11:22:23Z","timestamp":1543576943000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antimicrobial activity of ceftolozane\u2013tazobactam tested against gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers"],"prefix":"10.1016","volume":"94","author":[{"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QCO.0000000000000438","article-title":"New antibiotics for ventilator-associated pneumonia","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1040841X.2013.875515","article-title":"Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - review of the literature from a clinical perspective","volume":"42","author":"Biehl","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0015","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/AAC.02252-12","article-title":"Prevalence of beta-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010)","volume":"57","author":"Castanheira","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0025","author":"Centers for Disease Control & Prevention (CDC)"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0030","author":"Centers for Disease Control & Prevention (CDC)"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0035","series-title":"M07Ed11E. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eleventh edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0040","series-title":"M100Ed28E. Performance standards for antimicrobial susceptibility testing: 28th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0045","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0050","author":"EMA"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0055","author":"EUCAST"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0060","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0070","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/civ629","article-title":"Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006\u20132010","volume":"61","author":"Jones","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0075","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use beta-lactam\/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase\u2013producing bacteria?","volume":"54","author":"Perez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0095","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase\u2013producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0115","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1060028015593293","article-title":"Ceftolozane\/tazobactam: a new cephalosporin and beta-lactamase inhibitor combination","volume":"49","author":"Sucher","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem beta-lactams for the treatment of extended-spectrum beta-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.021_bb0125","series-title":"ZERBAXA\u00ae (ceftolozane\/tazobactam)","author":"ZERBAXA","year":"2016"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318304255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318304255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T06:00:32Z","timestamp":1662530432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318304255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0732889318304255"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.021","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}